{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:15:58Z","timestamp":1792430158014,"version":"4.5.0"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2020,12,1]]},"DOI":"10.1001\/jamadermatol.2020.3260","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T17:02:18Z","timestamp":1601485338000},"page":"1333","source":"Crossref","is-referenced-by-count":279,"title":["Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis"],"prefix":"10.1001","volume":"156","author":[{"given":"Kristian","family":"Reich","sequence":"first","affiliation":[{"name":"Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"},{"name":"Skinflammation Center, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Kabashima","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Kyoto University, Kyoto, Japan"},{"name":"Skin Research Institute of Singapore and Singapore Immunology Network, A*Star, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketty","family":"Peris","sequence":"additional","affiliation":[{"name":"Dermatologia, Fondazione Policlinico Universitario A. Gemelli IRCCS- Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[{"name":"Department of Dermatology, George Washington University School of Medicine, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence F.","family":"Eichenfield","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, San Diego and Rady Children\u2019s Hospital, San Diego, California"},{"name":"Department of Pediatrics, University of California, San Diego and Rady Children\u2019s Hospital, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bieber","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, University Hospital of Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Kaszuba","sequence":"additional","affiliation":[{"name":"Dermed Centrum Medyczne, Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Kolodsick","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan E.","family":"Yang","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Gamalo","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis R.","family":"Brinker","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy M.","family":"DeLozier","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Janes","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio P.","family":"Nunes","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob P.","family":"Thyssen","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Hellerup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Simpson","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Oregon Health and Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"doi200053r1","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1111\/all.2018.73.issue-6","article-title":"Epidemiology of atopic dermatitis in adults: results from an international survey.","volume":"73","author":"Barbarot","year":"2018","journal-title":"Allergy"},{"issue":"5","key":"doi200053r2","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/j.jaip.2019.01.005","article-title":"Atopic dermatitis in US adults: from population to health care utilization.","volume":"7","author":"Silverberg","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"doi200053r3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.anai.2017.10.039","article-title":"Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape.","volume":"120","author":"Boguniewicz","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"doi200053r4","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","article-title":"Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study.","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"doi200053r5","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.anai.2017.09.076","article-title":"Burden of skin pain in atopic dermatitis.","volume":"119","author":"Vakharia","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"doi200053r6","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","article-title":"Guidelines of care for the management of atopic dermatitis, section 2: management and treatment of atopic dermatitis with topical therapies.","volume":"71","author":"Eichenfield","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"doi200053r7","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1111\/jdv.2012.26.issue-8","article-title":"Guidelines for treatment of atopic eczema (atopic dermatitis) part I.","volume":"26","author":"Ring","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"doi200053r8","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.alit.2016.12.003","article-title":"Japanese guidelines for atopic dermatitis 2017.","volume":"66","author":"Katayama","year":"2017","journal-title":"Allergol Int"},{"issue":"2","key":"doi200053r9","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","article-title":"Guidelines of care for the management of atopic dermatitis, section 3: management and treatment with phototherapy and systemic agents.","volume":"71","author":"Sidbury","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"doi200053r10","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/jdv.2012.26.issue-9","article-title":"Guidelines for treatment of atopic eczema (atopic dermatitis) part II.","volume":"26","author":"Ring","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"doi200053r13","doi-asserted-by":"publisher","first-page":"5298","DOI":"10.4049\/jimmunol.0902819","article-title":"Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.","volume":"184","author":"Fridman","year":"2010","journal-title":"J Immunol"},{"issue":"12","key":"doi200053r14","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"doi200053r15","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.anai.2018.02.012","article-title":"JAK\/STAT inhibitors and other small molecule cytokine antagonists for the treatment of allergic disease.","volume":"120","author":"Howell","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"doi200053r16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.anai.2019.10.005","article-title":"New treatments for atopic dermatitis targeting beyond IL-4\/IL-13 cytokines.","volume":"124","author":"Renert-Yuval","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"doi200053r17","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/bjd.v183.2","article-title":"Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials.","volume":"183","author":"Simpson","year":"2020","journal-title":"Br J Dermatol"},{"issue":"2","key":"doi200053r18","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jaad.2013.10.010","article-title":"Guidelines of care for the management of atopic dermatitis, section 1: diagnosis and assessment of atopic dermatitis.","volume":"70","author":"Eichenfield","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"20","key":"doi200053r19","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"4","key":"doi200053r22","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jaad.2018.01.018","article-title":"Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study.","volume":"80","author":"Guttman-Yassky","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"doi200053r23","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1016\/j.jaip.2019.05.055","article-title":"Pain is a common and burdensome symptom of atopic dermatitis in United States adults.","volume":"7","author":"Silverberg","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"doi200053r24","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1111\/bjd.v182.6","article-title":"Pain severity and use of analgesic medication in adults with atopic dermatitis: a cross-sectional study.","volume":"182","author":"Thyssen","year":"2020","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi200053r26","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/bjd.v181.3","article-title":"Conjunctivitis in dupilumab clinical trials.","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"issue":"10086","key":"doi200053r27","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"doi200053r20","volume-title":"The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD\u2122): A Clinical Outcome Measure for the Severity of Atopic Dermatitis","author":"Simpson","year":"2019"},{"key":"doi200053r11","unstructured":"Dupixent. Prescribing information. Regeneron Pharmaceuticals; October 2017. Reference ID: 4337903. Accessed June 7, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761055s007lbl.pdf"},{"key":"doi200053r12","unstructured":"Dupixent. Product information. Sanofi Deutschland GmbH. Accessed June 7, 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/dupixent-epar-product-information_en.pdf"},{"key":"doi200053r21","unstructured":"A study of long-term baricitinib (LY3009104) therapy in atopic dermatitis (BREEZE-AD3). ClinicalTrials.gov identifier: NCT03334435. Updated March 17, 2020. Accessed August 15, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03334435"},{"key":"doi200053r25","unstructured":"Olumiant. Prescribing information. Eli Lilly and Company; 2018. Reference ID: 4271150. Accessed March 28, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/207924s000lbl.pdf"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2771084\/jamadermatology_reich_2020_oi_200053_1607046290.82994.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T20:27:11Z","timestamp":1607545631000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2771084"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2020.3260","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,1]]}}}